Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
Public ClinicalTrials.gov record NCT00116831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
Study identification
- NCT ID
- NCT00116831
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 672 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2005 (Type not available)
- Primary completion
- Aug 2008 (Actual)
- Completion
- Aug 2008 (Actual)
- Last update posted
- Mar 23, 2017
2005 – 2008
United States locations
- U.S. sites
- 39
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Tucson | Arizona | 85745 | — |
| GSK Investigational Site | Burbank | California | 91505 | — |
| GSK Investigational Site | Huntington Beach | California | 92648 | — |
| GSK Investigational Site | Los Angeles | California | 90017 | — |
| GSK Investigational Site | Mission Viejo | California | 92691 | — |
| GSK Investigational Site | Sacramento | California | 95817 | — |
| GSK Investigational Site | Sacramento | California | 95825 | — |
| GSK Investigational Site | Torrance | California | 90503 | — |
| GSK Investigational Site | Torrance | California | 90509 | — |
| GSK Investigational Site | Denver | Colorado | 80220 | — |
| GSK Investigational Site | Englewood | Colorado | 80113 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Tampa | Florida | 33609 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Peoria | Illinois | 61615 | — |
| GSK Investigational Site | Springfield | Illinois | 62702 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46260 | — |
| GSK Investigational Site | Baltimore | Maryland | 21287 | — |
| GSK Investigational Site | Columbia | Maryland | 21044 | — |
| GSK Investigational Site | Springfield | Massachusetts | 01199 | — |
| GSK Investigational Site | Springfield | Missouri | 65807 | — |
| GSK Investigational Site | New Brunswick | New Jersey | 08903 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| GSK Investigational Site | Canton | Ohio | 44708 | — |
| GSK Investigational Site | Beaver | Pennsylvania | 15009 | — |
| GSK Investigational Site | Camp Hill | Pennsylvania | 17011 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19141 | — |
| GSK Investigational Site | Jackson | Tennessee | 38301 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78404 | — |
| GSK Investigational Site | San Antonio | Texas | 78207 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Bellevue | Washington | 98004 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00116831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00116831 live on ClinicalTrials.gov.